285 related articles for article (PubMed ID: 37153543)
21. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].
Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362
[No Abstract] [Full Text] [Related]
22. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
24. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
25. Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma.
Dong R; Wang Y; Sun X; Lin Y; Luo Y; Xing C; Sun L; Zhang S; Yu K; Jiang S; Chen Y
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):911-916. PubMed ID: 37777383
[TBL] [Abstract][Full Text] [Related]
26. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
Dima D; Abdallah AO; Davis JA; Awada H; Goel U; Rashid A; DeJarnette S; Anwer F; Shune L; Raza S; Mahmoudjafari Z; Williams L; Faiman B; McGuirk JP; Sauter CS; Ahmed N; Khouri J; Hashmi H
Blood Cancer J; 2024 May; 14(1):90. PubMed ID: 38821914
[TBL] [Abstract][Full Text] [Related]
27. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.
Rejeski K; Hansen DK; Bansal R; Sesques P; Ailawadhi S; Logue JM; Bräunlein E; Cordas Dos Santos DM; Freeman CL; Alsina M; Theurich S; Wang Y; Krackhardt AM; Locke FL; Bachy E; Jain MD; Lin Y; Subklewe M
J Hematol Oncol; 2023 Jul; 16(1):88. PubMed ID: 37525244
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
30. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Gagelmann N; Dima D; Merz M; Hashmi H; Ahmed N; Tovar N; Oliver-Caldés A; Stölzel F; Rathje K; Fischer L; Born P; Schäfer L; Albici AM; Schub N; Kfir-Erenfeld S; Assayag M; Asherie N; Wulf GG; Kharboutli S; Müller F; Shune L; Davis JA; Anwer F; Vucinic V; Platzbecker U; Ayuk F; Kröger N; Khouri J; Gurnari C; McGuirk J; Stepensky P; Abdallah AO; Fernández de Larrea C
J Clin Oncol; 2024 May; 42(14):1665-1675. PubMed ID: 38358946
[TBL] [Abstract][Full Text] [Related]
31. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy.
Akhtar OS; Modi K; Kim J; Skelson L; Smith E; Al-Jumayli MA; Extermann M; De Avila G; Parker N; Castaneda Puglianini O; Grajales Cruz A; Baz R; Blue B; Shain K; Alsina M; Liu H; Nishihori T; Jain MD; Locke FL; Hansen DK; Freeman CL
Transplant Cell Ther; 2024 Mar; 30(3):283.e1-283.e10. PubMed ID: 38123069
[TBL] [Abstract][Full Text] [Related]
32. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Qu X; An G; Sui W; Wang T; Zhang X; Yang J; Zhang Y; Zhang L; Zhu D; Huang J; Zhu S; Yao X; Li J; Zheng C; Zhu K; Wei Y; Lv X; Lan L; Yao Y; Zhou D; Lu P; Qiu L; Li J
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100310
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
Chen W; Wang Y; Qi K; Shi M; Cao J; Bhansali R; Wang X; Liu Y; Li H; Zhang H; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
Transplant Cell Ther; 2021 Mar; 27(3):273.e1-273.e5. PubMed ID: 33781540
[TBL] [Abstract][Full Text] [Related]
36. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
37. [Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA].
Sun Q; Qi YK; Qi KM; Yan ZL; Cheng H; Chen W; Zhu F; Sang W; Li DP; Cao J; Shi M; Li ZY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):832-837. PubMed ID: 38049335
[No Abstract] [Full Text] [Related]
38. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
Reyes KR; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Olin RL; Martin T; Shah N; Banerjee R
Transplant Cell Ther; 2023 Jun; 29(6):350-355. PubMed ID: 36933659
[TBL] [Abstract][Full Text] [Related]
39. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
Mahmood SS; Riedell PA; Feldman S; George G; Sansoterra SA; Althaus T; Rehman M; Mead E; Liu JE; Devereux RB; Weinsaft JW; Kim J; Balkan L; Barbar T; Lee Chuy K; Harchandani B; Perales MA; Geyer MB; Park JH; Palomba ML; Shouval R; Tomas AA; Shah GL; Yang EH; Gaut DL; Rothberg MV; Horn EM; Leonard JP; Van Besien K; Frigault MJ; Chen Z; Mehrotra B; Neilan TG; Steingart RM
Eur Heart J; 2023 Jun; 44(22):2029-2042. PubMed ID: 36939851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]